(Q28269998)

English

A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study

scientific article

In more languages

Statements

scholarly article

0 references

A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study (English)

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

author name string

N Shafiq

1

0 references

S Malhotra

2

0 references

P Pandhi

3

0 references

N Sharma

4

0 references

A Bhalla

5

0 references

A Grover

6

0 references

language of work or name

0 references

publication date

2006

0 references

0 references

78

0 references

3

0 references

136-43

0 references

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1159%2F000096484

21 January 2018

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

https://api.crossref.org/works/10.1159%2F000096484

21 January 2018

Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events

1 reference

https://api.crossref.org/works/10.1159%2F000096484

21 January 2018

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1159%2F000096484

21 January 2018

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

1 reference

https://api.crossref.org/works/10.1159%2F000096484

21 January 2018

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

1 reference

https://api.crossref.org/works/10.1159%2F000096484

21 January 2018

Identifiers

10.1159/000096484

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28269998&oldid=1573892250"